PMID- 22135121
OWN - NLM
STAT- MEDLINE
DCOM- 20120424
LR  - 20211021
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 16
IP  - 12
DP  - 2011
TI  - The outcomes and safety of single-agent sorafenib in the treatment of elderly 
      patients with advanced hepatocellular carcinoma (HCC).
PG  - 1721-8
LID - 10.1634/theoncologist.2011-0192 [doi]
AB  - BACKGROUND: With the aging population, hepatocellular carcinoma (HCC) in the 
      elderly represents a significant health burden. We aimed to evaluate and compare 
      the efficacy and tolerability of single-agent sorafenib in treating elderly 
      patients with advanced HCC versus the younger population. METHODS: We 
      retrospectively analyzed a consecutive cohort of advanced HCC patients with 
      Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group 
      performance status score of 0-2 treated with sorafenib. The patients were 
      categorized into older (age >/=70 years) and younger (age <70 years) groups. 
      Treatment outcomes and related adverse events (AEs) were compared. RESULTS: In 
      total, 172 patients, 35 in the older (median age, 73 years) and 137 in the 
      younger (median age, 55 years) group, were analyzed. The median progression-free 
      survival time was similar in the older and younger groups (2.99 months versus 
      3.09 months; p = .275), as was the overall survival time (5.32 months versus 5.16 
      months; p = .310). Grade 3 or 4 AEs were observed in 68.6% of older and 62.7% of 
      younger patients (p = .560), with neutropenia (11.4% versus 0.7%; p = .007), 
      malaise (11.4% versus 2.2%; p = .033), and mucositis (5.7% versus 0.0%; p = .041) 
      being more frequently reported in the elderly cohort. CONCLUSIONS: The survival 
      benefits and overall treatment-related AEs of sorafenib are comparable in elderly 
      and younger advanced HCC patients. Nevertheless, more vigilant monitoring in the 
      elderly is warranted because they are more susceptible to develop neutropenia, 
      malaise, and mucositis.
FAU - Wong, Hilda
AU  - Wong H
AD  - Department of Medicine, Queen Mary Hospital, Hong Kong.
FAU - Tang, Yuen Fong
AU  - Tang YF
FAU - Yao, Tzy-Jyun
AU  - Yao TJ
FAU - Chiu, Joanne
AU  - Chiu J
FAU - Leung, Roland
AU  - Leung R
FAU - Chan, Pierre
AU  - Chan P
FAU - Cheung, Tan To
AU  - Cheung TT
FAU - Chan, Albert C
AU  - Chan AC
FAU - Pang, Roberta W
AU  - Pang RW
FAU - Poon, Ronnie
AU  - Poon R
FAU - Fan, Sheung-Tat
AU  - Fan ST
FAU - Yau, Thomas
AU  - Yau T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20111201
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Benzenesulfonates/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Pyridines/*therapeutic use
MH  - Retrospective Studies
MH  - Sorafenib
MH  - Treatment Outcome
PMC - PMC3248771
COIS- Disclosures: Hilda Wong: None; Yuen Fong Tang: None; Tzy-Jyun Yao: None; Joanne 
      Chiu: None; Roland Leung: None; Pierre Chan: None; Tan To Cheung: None; Albert C. 
      Chan: None; Roberta W. Pang: None; Ronnie Poon: Bayer Pharmaceuticals Limited 
      (RF); Sheung-Tat Fan: None; Thomas Yau: Bayer Schering (C/A).
EDAT- 2011/12/03 06:00
MHDA- 2012/04/25 06:00
PMCR- 2012/12/01
CRDT- 2011/12/03 06:00
PHST- 2011/12/03 06:00 [entrez]
PHST- 2011/12/03 06:00 [pubmed]
PHST- 2012/04/25 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - theoncologist.2011-0192 [pii]
AID - 3737266 [pii]
AID - 10.1634/theoncologist.2011-0192 [doi]
PST - ppublish
SO  - Oncologist. 2011;16(12):1721-8. doi: 10.1634/theoncologist.2011-0192. Epub 2011 
      Dec 1.